文献速递关节外科创伤骨科

度洛西汀对全膝关节置换术后阿片类药物使用及疼痛的影响:三盲随机对照试验

Effect of Duloxetine on Opioid Use and Pain After Total Knee Arthroplasty: A Triple-Blinded Randomized Controlled Trial.
PubMed 文献 · J Arthroplasty · 2022-02-18

这项三盲随机对照试验纳入160例全膝关节置换术患者,每日给予60 mg度洛西汀或安慰剂,从手术当天持续至术后14天。度洛西汀在两个主要结局上非劣于安慰剂,且在阿片类药物消耗上优于安慰剂;作者认为在可适当监测潜在副作用的选定患者中,度洛西汀可用于减少膝关节置换术后的阿片类药物使用。

要点

  • 度洛西汀60 mg每日一次从手术当天用至术后14天,在活动时疼痛评分和累积阿片消耗两个主要结局上非劣于安慰剂。
  • 阿片消耗(均值±标准差)度洛西汀组288±226 mg OME vs 安慰剂组432±374 mg OME,P=.0039,度洛西汀组更低。
  • 术后第14天疼痛评分度洛西汀组4.2±2.0 vs 安慰剂组4.8±2.2,P=.018;疼痛管理满意度中位数10(8,10)vs 8(7,10),P=.046。

核心结论

  • 度洛西汀在两个主要结局上非劣于安慰剂,且在阿片类药物消耗上优于安慰剂。
  • 阿片使用减少29%,相当于少用17片5 mg羟考酮,且未增加疼痛评分。
  • 考虑到阿片类药物流行,作者认为在可适当监测药物潜在副作用的选定患者中,度洛西汀可用于减少膝关节置换术后的阿片类药物使用。

研究设计与样本

  • 三盲随机对照试验,共160例患者每日接受60 mg度洛西汀或安慰剂,从手术当天开始持续至术后14天。
  • 患者接受椎管内麻醉、外周神经阻滞、对乙酰氨基酚、非甾体抗炎药及按需口服阿片类药物。
  • 双主要结局为术后第1、2、14天活动时数字评定量表(NRS)评分,以及手术至术后第14天的累积阿片消耗量。

主要发现

  • 阿片消耗(均值±标准差)度洛西汀组288±226 mg OME vs 安慰剂组432±374 mg OME,P=.0039,度洛西汀组更低。
  • 术后第14天疼痛评分度洛西汀组4.2±2.0 vs 安慰剂组4.8±2.2,P=.018,度洛西汀组更低。
  • 疼痛管理满意度中位数度洛西汀组10(8,10)vs 安慰剂组8(7,10),P=.046,度洛西汀组更高。
  • 度洛西汀减少了疼痛对行走、正常工作及睡眠的干扰。

关键数值与推荐

  • 度洛西汀组阿片消耗288±226 mg OME vs 安慰剂组432±374 mg OME,P=.0039。
  • 术后第14天疼痛评分度洛西汀组4.2±2.0 vs 安慰剂组4.8±2.2,P=.018。
  • 疼痛管理满意度中位数度洛西汀组10(8,10)vs 安慰剂组8(7,10),P=.046。
  • 阿片使用减少29%,相当于少用17片5 mg羟考酮。

临床怎么用

  • 作者认为,考虑到阿片类药物流行,在可适当监测药物潜在副作用的选定患者中,度洛西汀可用于减少膝关节置换术后的阿片类药物使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Duloxetine, a serotonin-norepinephrine dual reuptake inhibitor, may improve analgesia after total knee arthroplasty (TKA). Previous studies had one primary outcome, did not consistently use multimodal analgesia, and used patient-controlled analgesia devices, potentially delaying discharge. We investigated whether duloxetine would reduce opioid consumption or pain with ambulation. METHODS: A total of 160 patients received 60 mg duloxetine or placebo daily, starting from the day of surgery and continuing 14 days postoperatively. Patients received neuraxial anesthesia, peripheral nerve blocks, acetaminophen, nonsteroidal anti-inflammatory drugs, and oral opioids as needed. The dual primary outcomes were Numeric Rating Scale (NRS) scores with movement on postoperative days 1, 2, and 14, and cumulative opioid consumption surgery through postoperative day 14. RESULTS: Duloxetine was noninferior to placebo for both primary outcomes and was superior to placebo for opioid consumption. Opioid consumption (mean ± SD) was 288 ± 226 mg OME [94, 385] vs 432 ± 374 [210, 540] (duloxetine vs placebo) P = .0039. Pain scores on POD14 were 4.2 ± 2.0 vs 4.8 ± 2.2 (duloxetine vs placebo) P = .018. Median satisfaction with pain management was 10 (8, 10) and 8 (7, 10) (duloxetine vs placebo) P = .046. Duloxetine reduced interference by pain with walking, normal work, and sleep. CONCLUSION: The 29% reduction in opioid use corresponds to 17 fewer pills of oxycodone, 5 mg, and was achieved without increasing pain scores. Considering the ongoing opioid epidemic, duloxetine can be used to reduce opioid usage after knee arthroplasty in selected patients that can be appropriately monitored for potential side effects of the medication.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. YaDeau JT, Mayman DJ, Jules-Elysee KM, et al. Effect of Duloxetine on Opioid Use and Pain After Total Knee Arthroplasty: A Triple-Blinded Randomized Controlled Trial. J Arthroplasty. 2022. PMID: 35346549. doi:10.1016/j.arth.2022.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。